Previous 10 | Next 10 |
SAN FRANCISCO, May 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced the appointment of Noreen R...
The FDA has signed off on Fast Track status for Yantai, China-based RemeGen 's lead drug RC18 for the treatment of systemic lupus erythematosus (SLE). More news on: GlaxoSmithKline plc, Mallinckrodt plc, Biogen Inc., Healthcare stocks news, Read more ...
Kezar Life Sciences (NASDAQ: KZR ) has issued the following statement regarding the COVID-19 pandemic: More news on: Kezar Life Sciences, Inc., Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., April 09, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today issued the following ...
Phase 2 MARINA, MISSION and PRESIDIO trials with KZR-616 are progressing Additional data from the ongoing Phase 1b portion of the MISSION study to be presented during various medical conferences throughout the course of 2020 KZR-261, a first-in-class protein secretion inhibitor, i...
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmunity and cancer, today announced its Chief Executi...
Gainers: vTv Therapeutics (NASDAQ: VTVT ) +57% . More news on: vTv Therapeutics Inc., Taubman Centers, Inc., NanoViricides, Inc., Stocks on the move, , Read more ...
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the cl...
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 (GLOBE NEWSWIRE) -- Kezar Life Sciences, Inc. (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced th...
Kezar Life Sciences (NASDAQ: KZR ) has traded down as much as 12.6% in light postmarket action after proposing a public offering of stock and prefunded warrants. More news on: Kezar Life Sciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Kezar Life Sciences Inc. Company Name:
KZR Stock Symbol:
NASDAQ Market:
Kezar Life Sciences Inc. Website:
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that Chris Kirk, Co-founder and Chief Executive Officer, will participate in a fireside chat at...
PALIZADE Phase 2b clinical trial of zetomipzomib in patients with active lupus nephritis actively enrolling; reiterating guidance of topline data in mid-2026 PORTOLA Phase 2a clinical trial of zetomipzomib in patients with autoimmune hepatitis actively enrolling; reiterating guidance of t...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...